Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 211

1.

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O'Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS.

N Engl J Med. 2019 Sep 28. doi: 10.1056/NEJMoa1910231. [Epub ahead of print]

PMID:
31562796
2.

Targeting NF-κB-mediated inflammatory pathways in cisplatin-resistant NSCLC.

Ryan SL, Beard S, Barr MP, Umezawa K, Heavey S, Godwin P, Gray SG, Cormican D, Finn SP, Gately KA, Davies AM, Thompson EW, Richard DJ, O'Byrne KJ, Adams MN, Baird AM.

Lung Cancer. 2019 Sep;135:217-227. doi: 10.1016/j.lungcan.2019.07.006. Epub 2019 Jul 12.

PMID:
31446998
3.

Nivolumab plus ipilimumab in non-small-cell lung cancer.

Reck M, Borghaei H, O'Byrne KJ.

Future Oncol. 2019 Jul;15(19):2287-2302. doi: 10.2217/fon-2019-0031. Epub 2019 May 8.

4.

Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells.

Gaule P, Mukherjee N, Corkery B, Eustace AJ, Gately K, Roche S, O'Connor R, O'Byrne KJ, Walsh N, Duffy MJ, Crown J, O'Donovan N.

Cancers (Basel). 2019 Apr 17;11(4). pii: E548. doi: 10.3390/cancers11040548.

5.

When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?

Baird AM, Easty D, Jarzabek M, Shiels L, Soltermann A, Klebe S, Raeppel S, MacDonagh L, Wu C, Griggs K, Kirschner MB, Stanfill B, Nonaka D, Goparaju CM, Murer B, Fennell DA, O'Donnell DM, Barr MP, Mutti L, Reid G, Finn S, Cuffe S, Pass HI, Opitz I, Byrne AT, O'Byrne KJ, Gray SG.

Front Endocrinol (Lausanne). 2019 Feb 26;10:89. doi: 10.3389/fendo.2019.00089. eCollection 2019.

6.

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.

Ready N, Hellmann MD, Awad MM, Otterson GA, Gutierrez M, Gainor JF, Borghaei H, Jolivet J, Horn L, Mates M, Brahmer J, Rabinowitz I, Reddy PS, Chesney J, Orcutt J, Spigel DR, Reck M, O'Byrne KJ, Paz-Ares L, Hu W, Zerba K, Li X, Lestini B, Geese WJ, Szustakowski JD, Green G, Chang H, Ramalingam SS.

J Clin Oncol. 2019 Apr 20;37(12):992-1000. doi: 10.1200/JCO.18.01042. Epub 2019 Feb 20.

PMID:
30785829
7.

EV, Microvesicles/MicroRNAs and Stem Cells in Cancer.

Tickner JA, Richard DJ, O'Byrne KJ.

Adv Exp Med Biol. 2018;1056:123-135. doi: 10.1007/978-3-319-74470-4_8. Review.

PMID:
29754178
8.

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, Borghaei H, Ramalingam SS, Brahmer J, Reck M, O'Byrne KJ, Geese WJ, Green G, Chang H, Szustakowski J, Bhagavatheeswaran P, Healey D, Fu Y, Nathan F, Paz-Ares L.

N Engl J Med. 2018 May 31;378(22):2093-2104. doi: 10.1056/NEJMoa1801946. Epub 2018 Apr 16.

9.

BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC.

MacDonagh L, Gray SG, Breen E, Cuffe S, Finn SP, O'Byrne KJ, Barr MP.

Cancer Lett. 2018 Aug 1;428:117-126. doi: 10.1016/j.canlet.2018.04.008. Epub 2018 Apr 11.

PMID:
29653268
10.

Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi.

Suraweera A, O'Byrne KJ, Richard DJ.

Front Oncol. 2018 Mar 29;8:92. doi: 10.3389/fonc.2018.00092. eCollection 2018. Review.

11.

Development and characterisation of a panel of phosphatidylinositide 3-kinase - mammalian target of rapamycin inhibitor resistant lung cancer cell lines.

Heavey S, Dowling P, Moore G, Barr MP, Kelly N, Maher SG, Cuffe S, Finn SP, O'Byrne KJ, Gately K.

Sci Rep. 2018 Jan 26;8(1):1652. doi: 10.1038/s41598-018-19688-1.

12.

Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC.

MacDonagh L, Gallagher MF, Ffrench B, Gasch C, Breen E, Gray SG, Nicholson S, Leonard N, Ryan R, Young V, O'Leary JJ, Cuffe S, Finn SP, O'Byrne KJ, Barr MP.

Oncotarget. 2017 Aug 3;8(42):72544-72563. doi: 10.18632/oncotarget.19881. eCollection 2017 Sep 22.

13.

Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines.

Collins DM, Gately K, Hughes C, Edwards C, Davies A, Madden SF, O'Byrne KJ, O'Donovan N, Crown J.

Cell Immunol. 2017 Sep;319:35-42. doi: 10.1016/j.cellimm.2017.07.005. Epub 2017 Jul 15.

PMID:
28735814
14.

hSSB1 associates with and promotes stability of the BLM helicase.

Croft LV, Ashton NW, Paquet N, Bolderson E, O'Byrne KJ, Richard DJ.

BMC Mol Biol. 2017 May 15;18(1):13. doi: 10.1186/s12867-017-0090-3.

15.

Nucleolar caspase-2: Protecting us from DNA damage.

O'Byrne KJ, Richard DJ.

J Cell Biol. 2017 Jun 5;216(6):1521-1523. doi: 10.1083/jcb.201704114. Epub 2017 May 12.

16.

Expression of CDCA3 Is a Prognostic Biomarker and Potential Therapeutic Target in Non-Small Cell Lung Cancer.

Adams MN, Burgess JT, He Y, Gately K, Snell C, Zhang SD, Hooper JD, Richard DJ, O'Byrne KJ.

J Thorac Oncol. 2017 Jul;12(7):1071-1084. doi: 10.1016/j.jtho.2017.04.018. Epub 2017 May 6.

17.

hSSB1 phosphorylation is dynamically regulated by DNA-PK and PPP-family protein phosphatases.

Ashton NW, Paquet N, Shirran SL, Bolderson E, Kariawasam R, Touma C, Fallahbaghery A, Gamsjaeger R, Cubeddu L, Botting C, Pollock PM, O'Byrne KJ, Richard DJ.

DNA Repair (Amst). 2017 Jun;54:30-39. doi: 10.1016/j.dnarep.2017.03.006. Epub 2017 Apr 6.

18.

Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma.

Cregan S, Breslin M, Roche G, Wennstedt S, MacDonagh L, Albadri C, Gao Y, O'Byrne KJ, Cuffe S, Finn SP, Gray SG.

Int J Oncol. 2017 Mar;50(3):1044-1052. doi: 10.3892/ijo.2017.3870. Epub 2017 Feb 9.

PMID:
28197626
19.

Novel insight into the composition of human single-stranded DNA-binding protein 1 (hSSB1)-containing protein complexes.

Ashton NW, Loo D, Paquet N, O'Byrne KJ, Richard DJ.

BMC Mol Biol. 2016 Dec 9;17(1):24.

20.

Activation and cleavage of SASH1 by caspase-3 mediates an apoptotic response.

Burgess JT, Bolderson E, Adams MN, Baird AM, Zhang SD, Gately KA, Umezawa K, O'Byrne KJ, Richard DJ.

Cell Death Dis. 2016 Nov 10;7(11):e2469. doi: 10.1038/cddis.2016.364.

21.

SASH1 mediates sensitivity of breast cancer cells to chloropyramine and is associated with prognosis in breast cancer.

Burgess JT, Bolderson E, Saunus JM, Zhang SD, Reid LE, McNicol AM, Lakhani SR, Cuff K, Richard K, Richard DJ, O'Byrne KJ.

Oncotarget. 2016 Nov 8;7(45):72807-72818. doi: 10.18632/oncotarget.12020.

22.

How does the timing of chemotherapy affect outcome following radical surgery for malignant pleural mesothelioma?

Sharkey AJ, O'Byrne KJ, Nakas A, Tenconi S, Fennell DA, Waller DA.

Lung Cancer. 2016 Oct;100:5-13. doi: 10.1016/j.lungcan.2016.07.023. Epub 2016 Jul 22.

PMID:
27597274
23.

Anti-cancer effects of baicalein in non-small cell lung cancer in-vitro and in-vivo.

Cathcart MC, Useckaite Z, Drakeford C, Semik V, Lysaght J, Gately K, O'Byrne KJ, Pidgeon GP.

BMC Cancer. 2016 Sep 1;16:707. doi: 10.1186/s12885-016-2740-0.

24.

Nucleophosmin: from structure and function to disease development.

Box JK, Paquet N, Adams MN, Boucher D, Bolderson E, O'Byrne KJ, Richard DJ.

BMC Mol Biol. 2016 Aug 24;17(1):19. doi: 10.1186/s12867-016-0073-9. Review.

25.

A structural analysis of DNA binding by hSSB1 (NABP2/OBFC2B) in solution.

Touma C, Kariawasam R, Gimenez AX, Bernardo RE, Ashton NW, Adams MN, Paquet N, Croll TI, O'Byrne KJ, Richard DJ, Cubeddu L, Gamsjaeger R.

Nucleic Acids Res. 2016 Sep 19;44(16):7963-73. doi: 10.1093/nar/gkw617. Epub 2016 Jul 7.

26.

hSSB1 (NABP2/OBFC2B) is regulated by oxidative stress.

Paquet N, Adams MN, Ashton NW, Touma C, Gamsjaeger R, Cubeddu L, Leong V, Beard S, Bolderson E, Botting CH, O'Byrne KJ, Richard DJ.

Sci Rep. 2016 Jun 8;6:27446. doi: 10.1038/srep27446.

27.

Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer.

Decatris MP, O'Byrne KJ.

Future Oncol. 2016 Aug;12(15):1805-22. doi: 10.2217/fon-2016-0086. Epub 2016 Jun 8. Review.

PMID:
27267211
28.

Drug Discovery Approaches Utilizing Three-Dimensional Cell Culture.

Ryan SL, Baird AM, Vaz G, Urquhart AJ, Senge M, Richard DJ, O'Byrne KJ, Davies AM.

Assay Drug Dev Technol. 2016 Jan-Feb;14(1):19-28. doi: 10.1089/adt.2015.670. Epub 2016 Jan 27. Review. Erratum in: Assay Drug Dev Technol. 2016 Apr;14(3):213.

PMID:
26866750
29.

Lung cancer stem cells: The root of resistance.

MacDonagh L, Gray SG, Breen E, Cuffe S, Finn SP, O'Byrne KJ, Barr MP.

Cancer Lett. 2016 Mar 28;372(2):147-56. doi: 10.1016/j.canlet.2016.01.012. Epub 2016 Jan 18. Review.

PMID:
26797015
30.

KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma.

Cregan S, McDonagh L, Gao Y, Barr MP, O'Byrne KJ, Finn SP, Cuffe S, Gray SG.

Int J Oncol. 2016 Mar;48(3):1290-6. doi: 10.3892/ijo.2016.3335. Epub 2016 Jan 13.

PMID:
26780987
31.
32.

Clinician Perspective on Molecular Profiling of Non-Small-Cell Lung Cancer.

Decatris MP, Farrugia D, O'Byrne KJ.

J Clin Oncol. 2016 Mar 10;34(8):884-6. doi: 10.1200/JCO.2015.65.2040. Epub 2016 Jan 11. No abstract available.

PMID:
26755521
33.

Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer.

O'Callaghan DS, Rexhepaj E, Gately K, Coate L, Delaney D, O'Donnell DM, Kay E, O'Connell F, Gallagher WM, O'Byrne KJ.

Eur Respir J. 2015 Dec;46(6):1762-72. doi: 10.1183/13993003.00176-2014. Epub 2015 Nov 5.

34.

VEGF-mediated cell survival in non-small-cell lung cancer: implications for epigenetic targeting of VEGF receptors as a therapeutic approach.

Barr MP, O'Byrne KJ, Al-Sarraf N, Gray SG.

Epigenomics. 2015;7(6):897-910. doi: 10.2217/epi.15.51. Epub 2015 Oct 7.

PMID:
26479311
35.

hSSB1 (NABP2/ OBFC2B) is required for the repair of 8-oxo-guanine by the hOGG1-mediated base excision repair pathway.

Paquet N, Adams MN, Leong V, Ashton NW, Touma C, Gamsjaeger R, Cubeddu L, Beard S, Burgess JT, Bolderson E, O'Byrne KJ, Richard DJ.

Nucleic Acids Res. 2015 Oct 15;43(18):8817-29. doi: 10.1093/nar/gkv790. Epub 2015 Aug 10.

36.

Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer.

Barr MP, Gray SG, Gately K, Hams E, Fallon PG, Davies AM, Richard DJ, Pidgeon GP, O'Byrne KJ.

Mol Cancer. 2015 Feb 20;14:45. doi: 10.1186/s12943-015-0310-8.

37.

The emerging role of microRNAs in resistance to lung cancer treatments.

MacDonagh L, Gray SG, Finn SP, Cuffe S, O'Byrne KJ, Barr MP.

Cancer Treat Rev. 2015 Feb;41(2):160-9. doi: 10.1016/j.ctrv.2014.12.009. Epub 2014 Dec 23. Review.

PMID:
25592062
38.

Néstor-Guillermo Progeria Syndrome: a biochemical insight into Barrier-to-Autointegration Factor 1, alanine 12 threonine mutation.

Paquet N, Box JK, Ashton NW, Suraweera A, Croft LV, Urquhart AJ, Bolderson E, Zhang SD, O'Byrne KJ, Richard DJ.

BMC Mol Biol. 2014 Dec 12;15:27. doi: 10.1186/s12867-014-0027-z.

39.

The role of DNA repair pathways in cisplatin resistant lung cancer.

O'Grady S, Finn SP, Cuffe S, Richard DJ, O'Byrne KJ, Barr MP.

Cancer Treat Rev. 2014 Dec;40(10):1161-70. doi: 10.1016/j.ctrv.2014.10.003. Epub 2014 Oct 18. Review.

PMID:
25458603
40.

Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters.

Peters S, Weder W, Dafni U, Kerr KM, Bubendorf L, Meldgaard P, O'Byrne KJ, Wrona A, Vansteenkiste J, Felip E, Marchetti A, Savic S, Lu S, Smit E, Dingemans AM, Blackhall FH, Baas P, Camps C, Rosell R, Stahel RA; ETOP Lungscape Investigators.

J Thorac Oncol. 2014 Nov;9(11):1675-84. doi: 10.1097/JTO.0000000000000320.

41.

Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project.

Blackhall FH, Peters S, Bubendorf L, Dafni U, Kerr KM, Hager H, Soltermann A, O'Byrne KJ, Dooms C, Sejda A, Hernández-Losa J, Marchetti A, Savic S, Tan Q, Thunnissen E, Speel EJ, Cheney R, Nonaka D, de Jong J, Martorell M, Letovanec I, Rosell R, Stahel RA.

J Clin Oncol. 2014 Sep 1;32(25):2780-7. doi: 10.1200/JCO.2013.54.5921. Epub 2014 Jul 28.

PMID:
25071109
42.

Strategic targeting of the PI3K-NFκB axis in cisplatin-resistant NSCLC.

Heavey S, Godwin P, Baird AM, Barr MP, Umezawa K, Cuffe S, Finn SP, O'Byrne KJ, Gately K.

Cancer Biol Ther. 2014 Oct;15(10):1367-77. doi: 10.4161/cbt.29841. Epub 2014 Jul 15.

43.

Functions and therapeutic roles of exosomes in cancer.

Tickner JA, Urquhart AJ, Stephenson SA, Richard DJ, O'Byrne KJ.

Front Oncol. 2014 May 27;4:127. doi: 10.3389/fonc.2014.00127. eCollection 2014. Review.

44.

Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promising.

Jekimovs C, Bolderson E, Suraweera A, Adams M, O'Byrne KJ, Richard DJ.

Front Oncol. 2014 Apr 22;4:86. doi: 10.3389/fonc.2014.00086. eCollection 2014. Review.

45.

Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer.

Douillard JY, Pirker R, O'Byrne KJ, Kerr KM, Störkel S, von Heydebreck A, Grote HJ, Celik I, Shepherd FA.

J Thorac Oncol. 2014 May;9(5):717-24. doi: 10.1097/JTO.0000000000000141.

46.

Prognostic impact of vascular and lymphovascular invasion in early lung cancer.

Al-Alao BS, Gately K, Nicholson S, McGovern E, Young VK, O'Byrne KJ.

Asian Cardiovasc Thorac Ann. 2014 Jan;22(1):55-64. doi: 10.1177/0218492313478431. Epub 2013 Sep 4.

PMID:
24585645
47.

Thromboxane synthase expression and correlation with VEGF and angiogenesis in non-small cell lung cancer.

Cathcart MC, Gately K, Cummins R, Drakeford C, Kay EW, O'Byrne KJ, Pidgeon GP.

Biochim Biophys Acta. 2014 May;1842(5):747-55. doi: 10.1016/j.bbadis.2014.01.011. Epub 2014 Jan 28.

48.

Genome stability pathways in head and neck cancers.

Jenkins G, O'Byrne KJ, Panizza B, Richard DJ.

Int J Genomics. 2013;2013:464720. doi: 10.1155/2013/464720. Epub 2013 Nov 4. Review.

49.

Predictive values for molecular diagnostics: converting unknown unknowns to known unknowns.

O'Brien CP, Langabeer SE, O'Byrne KJ, O'Leary JJ, Finn SP.

Mol Diagn Ther. 2014 Feb;18(1):1-4. doi: 10.1007/s40291-013-0076-x. No abstract available.

PMID:
24338436
50.

Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer.

Pujol JL, Pirker R, Lynch TJ, Butts CA, Rosell R, Shepherd FA, Vansteenkiste J, O'Byrne KJ, de Blas B, Heighway J, von Heydebreck A, Thatcher N.

Lung Cancer. 2014 Feb;83(2):211-8. doi: 10.1016/j.lungcan.2013.11.006. Epub 2013 Nov 16.

PMID:
24332319

Supplemental Content

Loading ...
Support Center